NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma

Thyroid

Volumn 24, Issue 8, 2014, Pages 1275-1281

  Jang, Eun Kyung ^a   Song, Dong Eun ^a   Sim, So Young ^a   Kwon, Hyemi ^a   Choi, Yun Mi ^a   Jeon, Min Ji ^a   Han, Ji Min ^a   Kim, Won Gu ^a   Kim, Tae Yong ^a   Shong, Young Kee ^a   Kim, Won Bae ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; B RAF KINASE; CODON; RAS PROTEIN;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; CODON; DISEASE ASSOCIATION; DISTANT METASTASIS; DNA SEQUENCE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; KIDNEY METASTASIS; LIVER METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; NODULAR HYPERPLASIA; ONCOGENE H RAS; ONCOGENE N RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; POINT MUTATION; PRIORITY JOURNAL; SURVIVAL TIME; THYROID FOLLICULAR CARCINOMA; THYROIDECTOMY; TUMOR INVASION; TUMOR VOLUME; ADENOCARCINOMA; ADENOMA; AGE; GENETICS; HYPERPLASIA; METABOLISM; METASTASIS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; THYROID TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; ADULT; AGE FACTORS; AGED; CODON; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; HYPERPLASIA; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 84904655833     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2014.0053     Document Type: Article

References (31)

1. Prior IA, Lewis PD, Mattos C 2012 A comprehensive survey of Ras mutations in cancer. Cancer Res 72:2457-2467.
2. Nikiforov YE 2008 Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 21:S37-S43. (Pubitemid 351592770)
3. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA 2009 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69:4885-4893.
4. Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B, Wynford-Thomas D 1989 High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4:159-164. (Pubitemid 19096939)
5. Namba H, Rubin SA, Fagin JA 1990 Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4:1474-1479. (Pubitemid 20356608)
6. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M 2007 Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 13:1161-1170. (Pubitemid 46424056)
7. Xing M 2013 Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13:184-199.
8. Manenti G, Pilotti S, Re FC, Della Porta G, Pierotti MA 1994 Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur J Cancer 30A: 987-993. (Pubitemid 24256250)
9. Fukahori M, Yoshida A, Hayashi H, Yoshihara M, Matsukuma S, Sakuma Y, Koizume S, Okamoto N, Kondo T, Masuda M, Miyagi Y 2012 The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. Thyroid 22:683-689.
10. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G 2003 ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21: 3226-3235. (Pubitemid 46606254)
11. Grebe SK, Hay ID 1995 Follicular thyroid cancer. Endocrinol Metab Clin North Am 24:761-801.
12. DeGroot LJ, Kaplan EL, Shukla MS, Salti G, Straus FH 1995 Morbidity and mortality in follicular thyroid cancer. J Clin Endocrinol Metab 80:2946-2953.
13. Passler C, Scheuba C, Prager G, Kaczirek K, Kaserer K, Zettinig G, Niederle B 2004 Prognostic factors of papillary and follicular thyroid cancer: differences in an iodinereplete endemic goiter region. Endocr-Relat Cancer 11: 131-139. (Pubitemid 38419728)
14. Ito Y, Hirokawa M, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A 2007 Prognosis and prognostic factors of follicular carcinoma in Japan: importance of postoperative pathological examination. World J Surg 31:1417-1424. (Pubitemid 46945384)
15. Asari R, Koperek O, Scheuba C, Riss P, Kaserer K, Hoffmann M, Niederle B 2009 Follicular thyroid carcinoma in an iodine-replete endemic goiter region: a prospectively collected, retrospectively analyzed clinical trial. Ann Surg 249:1023-1031.
16. Sugino K, Ito K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, Yano Y, Uruno T, Akaishi J, Kameyama K, Ito K 2011 Prognosis and prognostic factors for distant metastases and tumor mortality in follicular thyroid carcinoma. Thyroid 21:751-757.
17. Lang BH, Wong KP, Cheung CY, Wan KY, Lo CY 2013 Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis. Ann Surg Oncol 20: 1329-1335.
18. Kondo T, Ezzat S, Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nate Rev Cancer 61: 292-306.
19. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK, Xing M 2008 Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93:3106-3116.
20. Esapa CT, Johnson SJ, Kendall-Taylor P, Lennard TW, Harris PE 1999 Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol 50:529-535. (Pubitemid 29193238)
21. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C 2003 Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88:2745-2752. (Pubitemid 36724451)
22. Schulten HJ, Salama S, Al-Ahmadi A, Al-Mansouri Z, Mirza Z, Al-Ghamdi K, Al-Hamour OA, Huwait E, Gari M, Al-Qahtani MH, Al-Maghrabi J 2013 Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population. Anticancer Res 33:4779-4784.
23. Rochefort P, Caillou B, Michiels FM, Ledent C, Talbot M, Schlumberger M, Lavelle F, Monier R, Feunteun J 1996 Thyroid pathologies in transgenic mice expressing a human activated Ras gene driven by a thyroglobulin promoter. Oncogene 12:111-118. (Pubitemid 26041246)
24. Bond JA, Wyllie FS, Rowson J, Radulescu A, Wynford- Thomas D 1994 In vitro reconstruction of tumour initiation in a human epithelium. Oncogene 9:281-290. (Pubitemid 24020960)
25. Gire V, Wynford-Thomas D 2000 RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation. Oncogene 19:737-744. (Pubitemid 30107704)
26. Alvarez-Nunez F, Bussaglia E, Mauricio D, Ybarra J, Vilar M, Lerma E, de Leiva A, Matias-Guiu X, Thyroid Neoplasia Study G 2006 PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 16:17-23. (Pubitemid 43346499)
27. Miller KA, Yeager N, Baker K, Liao XH, Refetoff S, Di Cristofano A 2009 Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res 69: 3689-3694.
28. Aguirre-Ghiso JA 2007 Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7: 834-846. (Pubitemid 350006258)
29. Phay JE, Ringel MD 2013 Metastatic mechanisms in follicular cell-derived thyroid cancer. Endocr-Relat Cancer 20:R307-319.
30. Kwak JY 2013 Indications for fine needle aspiration in thyroid nodules. Endocrinol Metab 28:81-85.
31. Gupta N, Dasyam AK, Carty SE, Nikiforova MN, Ohori NP, Armstrong M, Yip L, Lebeau SO, McCoy KL, Coyne C, Stang MT, Johnson J, Ferris RL, Seethala R, Nikiforov YE, Hodak SP 2013 RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. J Clin Endocrinol Metab 98: E914-922.